Comparison

KRIBIOLISA™ Intact Brentuximab Vedotin ELISA

Item no. KRIS-KBI1032
Manufacturer Krishgen Biosystems
Amount 1 x 96 wells
Category
Type Elisa-Kit
Applications ELISA
Specific against Human (Homo sapiens), Mouse (Murine, Mus musculus), Rat (Rattus norvegicus)
Sensitivity 0.2 ug/ml
Dry ice Yes
ECLASS 10.1 32160605
ECLASS 11.0 32160605
UNSPSC 41116126
Shipping Condition Dry ice
Available
Manufacturers Category
Krishgen- Biopharma-PK-ADA; Biosimilars / Biotherapeutics; Pharmacokinetic Assays / Bioassays
HSN Code
38220090
Short Description
Quantitative immunoassay for Anti-Eculizumab
Manufacturers Sample Type
Serum and Plasma
Description
Enzyme Immunoassay for the quantitative determination of Daratumumab in serum, plasma and cell culture supernatant.


Daratumumab (trade name Darzalex) is an anti-cancer drug. It binds to CD38, which multiple myeloma cells overexpress. Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.Daratumumab was given breakthrough therapy drug status in 2013 for multiple myeloma. It was awarded orphan drug status for multiple myeloma, diffuse large B cell
lymphoma, follicular lymphoma, and mantle cell lymphoma.


Krishgen PK kits, developed using the innovator drug as calibrator, are used for the quantitation of serum protein drug levels, and can be used for biosimilar and generics research as well.

About the kit:
- Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
- Recovery rates are between 85 - 115%
- Ready to use with a standard protocol with break-apart pre-coated wells
- Validated as per US FDA guidelines for Bioassays
- Optimized for matrix effects to ensure higher sensitivity.
- Shelf life: 1 year

The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Daratumumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Daratumumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Daratumumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells
and color develops proportionally to the amount of Daratumumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
Shipping Temp
2 - 8 degrees C

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 1 x 96 wells
Available: In stock
available

Delivery expected until 10/16/2025 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close